STADA: Record first half year results - optimistic for further growth
08/26/2003 . Ad hoc Release
New record results in the first half of 2003 confirm STADA’s successful growth strategy.
Compared to the first half of the prior year, STADA increased its consolidated sales in the first half of 2003 by +16% to EUR 358.6 million. Compared to the first half of 2002, the three core segments generics, branded products and special pharmaceuticals grew by +28% with total sales of EUR 340.2 million. Due to the planned reduction of the commercial business, the sales of non-core activities (commercial business, Group holding company) declined by -57% to EUR 18.4 million. The core segments thus contributed 95% to consolidated sales (HY 2002: 86 %).
STADA also achieved records in consolidated net income in the first half of 2003. In the first six months of 2003, consolidated net income rose to EUR 23.2 million (up +17% compared to HY 2002), earnings before taxes (EBT) to EUR 40.3 million (up +22% compared to HY 2002) and earnings before interest and taxes (EBIT) to EUR 47.4 million (up +24% compared to HY 2002). Earnings per share for the first half of 2003 were EUR 1.16
(HY 2002: EUR 1.06, with approx. 6% fewer shares at that time); diluted EPS (in accordance with IAS 33.24) was EUR 1.07 (HY 2002: EUR 0.98).
In its outlook, STADA anticipates a successful continuation of the growth strategy. The company expects 2003 to be another record year with unchanged double-digit percentage growth rates for sales and earnings. Irrespective of any healthcare policy factors, from the present perspective, STADA expects the double-digit percentage growth in sales and earnings to continue in 2004 as well.
You'll find the complete half year report and the press release on the Internet at www.stada.com.
For more information, please contact:
STADA Arzneimittel AG
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506